Ignite Creation Date:
2024-07-17 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06466850
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-14
Brief Title:
Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Sponsor:
Isfahan University of Medical Sciences
Organization:
Isfahan University of Medical Sciences
Study Overview
Official Title:
The Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Present research focuses on the potential of exosomes which are small vesicles secreted by mesenchymal stem cells MSCs as a therapeutic approach for osteoarthritis OA
OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix Its associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase MMP and a disintegrin and metalloproteinase with thrombospondin motifs ADAMTS
MSCs have been explored as a new treatment for OA over the last decade1 Its suggested that the paracrine secretion of trophic factors in which exosomes play a crucial role contributes to the mechanism of MSC-based treatment of OA
Exosomes derived from MSCs may suppress OA development They carry bioactive molecules of the parental cells including non-coding RNAs ncRNAs and proteins and anti-inflammatory factors These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity
This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment
OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix Its associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase MMP and a disintegrin and metalloproteinase with thrombospondin motifs ADAMTS
MSCs have been explored as a new treatment for OA over the last decade1 Its suggested that the paracrine secretion of trophic factors in which exosomes play a crucial role contributes to the mechanism of MSC-based treatment of OA
Exosomes derived from MSCs may suppress OA development They carry bioactive molecules of the parental cells including non-coding RNAs ncRNAs and proteins and anti-inflammatory factors These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity
This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None